Biomedical Research Foundation Academy Of AthensAcademy Of Athens
Scientific Personnel

Athanassios Athanassios Argiris, MD, PhD
Affiliated Investigator

e-mail : aargiris@bioacademy.gr


Center :

Clinical, Experimental Surgery & Translational Research


Brief Bio

Dr. Athanassios (Ethan) Argiris is Professor of Medical Oncology at Thomas Jefferson University, Philadelphia, Pennsylvania, USA, and a consultant medical oncologist at Hygeia Hospital in Athens, Greece. He received his medical degree from the University of Athens Medical School. From 1994-2013, he held positions at several prestigious academic institutions in the United States. He trained in internal medicine at Mount Sinai Beth Israel and in medical oncology at Yale University. After serving on the faculty of Northwestern University as an Assistant Professor from 2000-2005, he joined the faculty at the University of Pittsburgh where he was promoted to Professor of Medicine in 2009. From 2011-2013 he was  Professor and Chief of Hematology/Oncology at the University of Texas Health Science Center at San Antonio and the holder of the A.B. Alexander Distinguished Chair in Oncology.
He is currently an Adjunct Professor at University of Texas and was elected Visiting Professor at the University of Crete in 2011. Dr. Argiris is the founding president of the Hellenic Society of Head and Neck Oncology (HeSHNO).  He is also a member of several international oncology organizations, including the Eastern Cooperative Oncology Group (ECOG), SWOG, European Organization for Research and Treatment of Cancer, American Society of Clinical Oncology (ASCO), and ESMO.

Professor Argiris’ research has been internationally recognized and focuses on the development of targeted and personalized therapies for head and neck cancers, as well as lung cancers. He has served as a principal investigator for more than 50 clinical trials and has published more than 250 articles and abstracts.  His studies relating to head and neck cancers have included targeted therapies, immunotherapy, and combination chemoradiotherapy. He is also an Associate Editor for the journal Head and Neck and has served on the editorial boards of several journals, including the Journal of Clinical Oncology.

Selected Publications

A. Argiris , B.E. Brockstein, D.J. Haraf, K.M. Stenson, B.B. Mittal, M.S. Kies, F.R. Rosen, B. Jovanovic, E.E.Vokes.“Competing causes of death and second primary tumors in patients with locoregionally advanced head and neck cancer treated with chemoradiotherapy” Clinical Cancer Research 2004;10:1956-62

A. Argiris, Y. Li, A. Forastiere.  “Prognostic factors and long-term survivorship in patients with recurrent or metastatic head and neck cancer: an analysis of two Eastern Cooperative Oncology Group randomized trials” Cancer 2004;101:2222-9

A. Argiris, M. Karamouzis, D. Raben, R. Ferris. “Head and neck cancer” Lancet 2008;371:1695-709

S.S. Ramalingam, M. Maitland, P. Frankel, A.E. Argiris, M. Koczywas, B. Gitlitz, S. Thomas, I. Espinoza-Delgado, E.E. Vokes, D.R. Gandara, C.P. Belani. “Randomized, double-blind, placebo-controlled phase II study of carboplatin and paclitaxel with or without vorinostat, a histone deacetylase inhibitor (HDAC), for first-line therapy of advanced non-small cell lung cancer (NCI 7863)” Journal of Clinical Oncology 2010;28:56-62

A. Tarhini, A. Kotsakis, R. Stoller, S. Dacic, W. Gooding, A. Argiris. “Phase II trial of  everolimus in previously treated small cell lung cancer” Clinical Cancer Research 2010;16:5900-7

A. Argiris, M.V. Karamouzis, W.E. Gooding, B.F. Branstetter, S. Zhong, L.E. Raez, P. Savvides, M. Romkes. “Phase II trial of pemetrexed and bevacizumab in patients with recurrent or metastatic head and neck cancer” Journal of Clinical Oncology 2011;29:1140-45

A. Argiris, A. G. Duffy, S. Kummar, N. L. Simone, M., Y. Arai, S. F. Rudy, V. Kannabiren, X. Yang, M. Jang, Z. Chen, T. Cooley-Zgela, S.G. Ramanand, A. Ahsan, M. K. Nyati, J.J. Wright, C. Van Waes. “Early tumor progression associated with enhanced EGFR signaling with bortezomib, cetuximab, and radiotherapy for head and neck cancer” Clinical Cancer Research 2011;17(17):5755-64

S.E. Wheeler, D.R. Siwak, R. Chai, C. LaValle, R.R. Seethala, Lin Wang, K. Cieply, C. Sherer, C. Joy, G. B. Mills, A. Argiris, J.M. Siegfried, J.R. Grandis, A.M. Egloff. “Tumor epidermal growth factor receptor (EGFR) and EGFR PY1068 are independent prognostic indicators for head and neck squamous cell carcinoma” Clinical Cancer Research 2012; 18: 2278-2289

A. Argiris, A.P. Kotsakis, T. Hoang, F.P. Worden, P. Savvides, M.K. Gibson, W. Gooding, G.R. Blumenschein Jr., H.X. Chen, J.R. Grandis, P.M. Harari, M.S. Kies, S. Kim.  “Cetuximab and bevacizumab: preclinical data and phase II trial in patients with recurrent or metastatic head and neck cancer” Annals of Oncology 2013 Jan;24(1):220-5.

A. Argiris, M. Ghebremichael, J. Gilbert, J. Lee, K. Sachidanandam, J. M. Kolesar, B. Burtness, A. A. Forastiere. “Phase III randomized, placebo-controlled trial of docetaxel with or without gefitinib in recurrent or metastatic head and neck cancer: an eastern cooperative oncology group trial” Journal of Clinical Oncology 2013 Apr 10;31(11):1405-14.

H-B Jie, P.J. Schuller, S.C. Lee, R.M. Srivastava, A. Argiris, S. Ferrone, T.L. Whiteside, R.L. Ferris. “CTLA-4+ Regulatory T Cells are Increased in Cetuximab Treated Head and Neck Cancer Patients, Suppress NK Cell Cytotoxicity and Correlate with Poor Prognosis” Cancer Res 2015;75:2200-10

A. Argiris, J.E. Bauman, J. Ohr, W. Gooding, D.E. Heron, U. Duvvuri, G.J. Kubicek, D.M. Posluszny, M. Vassilakopoulou, S. Kim, J.R. Grandis, J.T. Johnson, M.K. Gibson, D. A. Clump, J.T. Flaherty, S.I. Chiosea, B. Branstetter, R.L. Ferris. “Phase II randomized trial of radiation therapy, cetuximab and pemetrexed with or without bevacizumab in patients with locally advanced head and neck cancer” Annals of Oncology 2016;27:1594-600

PubMed:

PubMed Link